for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MacroGenics Inc

MGNX.OQ

Latest Trade

12.88USD

Change

-0.13(-1.00%)

Volume

874,784

Today's Range

12.66

 - 

13.28

52 Week Range

9.87

 - 

32.32

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.01
Open
12.97
Volume
874,784
3M AVG Volume
9.92
Today's High
13.28
Today's Low
12.66
52 Week High
32.32
52 Week Low
9.87
Shares Out (MIL)
48.89
Market Cap (MIL)
629.75
Forward P/E
-3.66
Dividend (Yield %)
--

Next Event

MacroGenics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Macrogenics Inc Reports Quarterly Loss Per Share of $0.65

MacroGenics Provides Update On Flotetuzumab Program In Acute Myeloid Leukemia

Macrogenics And I-Mab Announce Deal To Develop And Commercialize Enoblituzumab In Greater China

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Industry

Biotechnology & Drugs

Contact Info

9704 Medical Center Dr

+1.301.2515172

https://www.macrogenics.com/

Executive Leadership

Paulo F. Costa

Independent Chairman of the Board

Scott Koenig

President, Chief Executive Officer, Director

James Karrels

Chief Financial Officer, Senior Vice President, Secretary

Ezio Bonvini

Senior Vice President - Research, Chief Scientific Officer

Eric Risser

Senior Vice President - Business Development and Portfolio Management and Chief Business Officer

Key Stats

1.75 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.2K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-1.690

2017

-0.540

2018

-4.190

2019(E)

-3.516
Price To Earnings (TTM)
--
Price To Sales (TTM)
11.08
Price To Book (MRQ)
2.14
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-46.20
Return on Equity (TTM)
-40.35

Latest News

BRIEF-MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34

* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 1ST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Macrogenics Inc Prices Of Public Offering

* MACROGENICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Macrogenics Announces Proposed Public Offering Of Common Stock

* MACROGENICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Macrogenics Provides Update On Corporate Progress And 2017 Financial Results

* MACROGENICS PROVIDES UPDATE ON CORPORATE PROGRESS AND 2017 FINANCIAL RESULTS

BRIEF-Macrogenics Enters Research Collaboration With Roche

* MACROGENICS ENTERS RESEARCH COLLABORATION WITH ROCHE TO DEVELOP A NOVEL BISPECIFIC MOLECULE

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing Source text: (http://bit.ly/2A2CHjE) Further company coverage:

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

BRIEF-MacroGenics Q2 net loss per share $1.14

* MacroGenics provides update on corporate progress and second quarter 2017 financial results

BRIEF-Boxer Capital reports 5.5 pct passive stake in Macrogenics

* Boxer Capital, Llc reports 5.5 percent passive stake in Macrogenics Inc as of may 31, 2017 -sec filing Source text - http://bit.ly/2sVCckL Further company coverage:

BRIEF-Macrogenics provides update on corporate progress and Q1 2017 financial results

* Macrogenics provides update on corporate progress and 1st quarter 2017 financial results

BRIEF-Macrogenics announces registered direct offering of common stock

* Macrogenics announces registered direct offering of common stock

BRIEF-Macrogenics makes board changes

* Macrogenics Inc- on Jan 25, co announced an increase to number of members of company's board of directors from six to eight members- sec filing Source text for Eikon: Further company coverage:

BRIEF-Macrogenics files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed - SEC filing Source text: [http://bit.ly/2eBbLcf] Further company coverage:

BRIEF-Macrogenics Qtrly loss per share $0.97

* Q3 earnings per share view $-0.80, revenue view $12.5 million -- Thomson Reuters I/B/E/S

BRIEF-Takeda and Macrogenics announce conclusion of MGD010 license and option agreement

* Takeda and Macrogenics announce the conclusion of their MGD010 license and option agreement

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up